{"id":112424,"date":"2026-09-10T09:28:05","date_gmt":"2026-09-10T07:28:05","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/connecta-therapeutics-raises-e3-1-million-to-advance-the-clinical-development-of-its-fragile-x-syndrome-program\/"},"modified":"2026-09-10T15:51:38","modified_gmt":"2026-09-10T13:51:38","slug":"connecta-therapeutics-raises-e3-1-million-to-advance-the-clinical-development-of-its-fragile-x-syndrome-program","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/connecta-therapeutics-raises-e3-1-million-to-advance-the-clinical-development-of-its-fragile-x-syndrome-program\/","title":{"rendered":"CONNECTA Therapeutics raises \u20ac3.1 million to advance the clinical development of its Fragile X syndrome program"},"content":{"rendered":"

CONNECTA Therapeutics<\/a>, a clinical-stage biotechnology company pioneering the development of first-in-class neuroplasticity modulators to address unmet medical needs in Central Nervous System (CNS) disorders, has closed a \u20ac3.1 million funding round led by Clave Capital through its Innvierte Science Tech Clave Innohealth, F.C.R. fund, with participation from the company\u2019s existing investors, Inveready, CDTI Innvierte, and Prous Institute for Biomedical Research.<\/strong><\/p>\n

The new funding will support the clinical development of CTH120 in adult male patients with Fragile X syndrome (FXS), currently being evaluated in a Phase IIa clinical trial (NCT07654114).<\/p>\n

Jordi F\u00e0brega<\/strong>, Co-founder and CEO of CONNECTA Therapeutics, commented: \u201cThis financing represents a significant milestone for CONNECTA and contributes to our efforts to advance the development of CTH120 for FXS. We believe the Phase IIa data, expected by mid-2027, will be a major step forward in demonstrating the potential of CTH120 to address the biological mechanisms underlying this rare disease and improve the quality of life of patients living with FXS.\u201d<\/p>\n

Supported by preclinical evidence and Phase I safety data (NCT06480968), the Phase IIa study, launched in June 2026, is evaluating the safety, tolerability, and efficacy of CTH120 in 30 randomized adult male patients with FXS. The trial is being conducted at the Hospital del Mar Research Institute (HMRIB) and the Parc Taul\u00ed Research and Innovation Institute Foundation (I3PT), and will contribute to advancing biomarker identification in collaboration with the Centre for Genomic Regulation (CRG).<\/p>\n

The study is funded by the Spanish Ministry of Science, Innovation and Universities and the European Union\u2019s NextGenerationEU programme (Project Reference: CPP2022-009659). In parallel, CONNECTA is preparing the development of CTH120 in pediatric patients through the FRAXCURE<\/a> project.<\/p>\n

Ignacio Prieto Fern\u00e1ndez<\/strong>, Associate Investor at Clave Capital, said: \u201cCONNECTA has developed an innovative approach to addressing neuroplasticity in FXS, supported by a clear clinical development strategy and an experienced team. The company has successfully advanced CTH120 into Phase IIa, and we look forward to supporting the team as they reach this next milestone.\u201d<\/p>\n

Sara Secall<\/strong>, General Partner at Inveready, added: \u201cAs investors since the seed stage, we have supported CONNECTA throughout the progression of CTH120, from a promising scientific concept to clinical development. Our participation through our latest fund, BIO Fund IV, reflects our continued confidence in the team, its strategy, and the potential impact of the upcoming clinical milestones.\u201d<\/p>\n

As part of this financing round, Ignacio Prieto Fern\u00e1ndez<\/strong> will join CONNECTA\u2019s Board of Directors as Clave Capital\u2019s representative.<\/p>\n

\u00bb Link to the news:<\/strong> CONNECTA Therapeutic’s website [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

CONNECTA Therapeutics, a clinical-stage biotechnology company pioneering the development of first-in-class neuroplasticity modulators to address unmet medical needs in Central Nervous System (CNS) disorders, has closed a \u20ac3.1 million funding…<\/p>\n","protected":false},"author":14,"featured_media":112420,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[90],"tags":[277],"class_list":["post-112424","post","type-post","status-publish","format-standard","has-post-thumbnail","category-entities","tag-connecta-therapeutics-en"],"acf":[],"yoast_head":"\nCONNECTA Therapeutics raises \u20ac3.1 million to advance the clinical development of its Fragile X syndrome program - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"description\" content=\"The new funding will support the clinical development of CTH120 in adult male patients with Fragile X syndrome (FXS), currently being evaluated in a Phase IIa (NCT07654114).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CONNECTA Therapeutics raises \u20ac3.1 million to advance the clinical development of its Fragile X syndrome program - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"The new funding will support the clinical development of CTH120 in adult male patients with Fragile X syndrome (FXS), currently being evaluated in a Phase IIa (NCT07654114).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-10T07:28:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-10T13:51:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/09\/fotos-web-900x330-px-25.png\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"CONNECTA Therapeutics raises \u20ac3.1 million to advance the clinical development of its Fragile X syndrome program\",\"datePublished\":\"2026-09-10T07:28:05+00:00\",\"dateModified\":\"2026-09-10T13:51:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\\\/\"},\"wordCount\":432,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/fotos-web-900x330-px-25.png\",\"keywords\":[\"CONNECTA Therapeutics\"],\"articleSection\":[\"ENTITIES\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\\\/\",\"name\":\"CONNECTA Therapeutics raises \u20ac3.1 million to advance the clinical development of its Fragile X syndrome program - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/fotos-web-900x330-px-25.png\",\"datePublished\":\"2026-09-10T07:28:05+00:00\",\"dateModified\":\"2026-09-10T13:51:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"description\":\"The new funding will support the clinical development of CTH120 in adult male patients with Fragile X syndrome (FXS), currently being evaluated in a Phase IIa (NCT07654114).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/fotos-web-900x330-px-25.png\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/fotos-web-900x330-px-25.png\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CONNECTA Therapeutics raises \u20ac3.1 million to advance the clinical development of its Fragile X syndrome program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CONNECTA Therapeutics raises \u20ac3.1 million to advance the clinical development of its Fragile X syndrome program - Parc Cient\u00edfic de Barcelona","description":"The new funding will support the clinical development of CTH120 in adult male patients with Fragile X syndrome (FXS), currently being evaluated in a Phase IIa (NCT07654114).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\/","og_locale":"en_US","og_type":"article","og_title":"CONNECTA Therapeutics raises \u20ac3.1 million to advance the clinical development of its Fragile X syndrome program - Parc Cient\u00edfic de Barcelona","og_description":"The new funding will support the clinical development of CTH120 in adult male patients with Fragile X syndrome (FXS), currently being evaluated in a Phase IIa (NCT07654114).","og_url":"https:\/\/www.pcb.ub.edu\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2026-09-10T07:28:05+00:00","article_modified_time":"2026-09-10T13:51:38+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/09\/fotos-web-900x330-px-25.png","type":"image\/png"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Paula Ca\u00f1al","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"CONNECTA Therapeutics raises \u20ac3.1 million to advance the clinical development of its Fragile X syndrome program","datePublished":"2026-09-10T07:28:05+00:00","dateModified":"2026-09-10T13:51:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\/"},"wordCount":432,"image":{"@id":"https:\/\/www.pcb.ub.edu\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/09\/fotos-web-900x330-px-25.png","keywords":["CONNECTA Therapeutics"],"articleSection":["ENTITIES"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\/","url":"https:\/\/www.pcb.ub.edu\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\/","name":"CONNECTA Therapeutics raises \u20ac3.1 million to advance the clinical development of its Fragile X syndrome program - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/09\/fotos-web-900x330-px-25.png","datePublished":"2026-09-10T07:28:05+00:00","dateModified":"2026-09-10T13:51:38+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"description":"The new funding will support the clinical development of CTH120 in adult male patients with Fragile X syndrome (FXS), currently being evaluated in a Phase IIa (NCT07654114).","breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/09\/fotos-web-900x330-px-25.png","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/09\/fotos-web-900x330-px-25.png","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/connecta-therapeutics-aixeca-31-milions-deuros-per-avancar-en-el-desenvolupament-clinic-del-seu-programa-per-a-la-sindrome-x-fragil\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"CONNECTA Therapeutics raises \u20ac3.1 million to advance the clinical development of its Fragile X syndrome program"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/112424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=112424"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/112424\/revisions"}],"predecessor-version":[{"id":112464,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/112424\/revisions\/112464"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/112420"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=112424"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=112424"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=112424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}